Low-molecular-weight heparins in the prophylaxis and treatment of thromboembolic diseases;Niedermolekulare heparine. Prophylaxe und Therapie thromboembolischer Erkrankungen

Hautarzt

Volumn 48, Issue 11, 1997, Pages 852-864

  Harenberg, J ^a,b   Huhle, G ^a   Piazolo, L ^a   Malsch, R ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; MONOEMBOLEX; NADROPARIN; REVIPARIN; TINZAPARIN;

ARTICLE; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; THROMBOEMBOLISM;

BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOEMBOLISM;

EID: 0030775233     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050676     Document Type: Article

References (44)

1. McLean J: The thromboplastic action of cephalin. Am J Physiol 1916,41: 250.
2. Howell WH, Holt E: Two new fractions in blood coagulation. Heparin and proantithrombin. Am J Physiol 1918,47:328-341.
3. Harenberg J, de Vries JX: Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 1983;261: 287-292.
4. Barrowcliffe TW, Johnson A, Eggleton CA, Kemball-Cook G, Thomas DP: Anticoagulant activities of high and low-molecular-weight heparin fractions. Br J Haematol 1979,41:573-582.
5. Barrowcliffe TW, Curtis AD, Johnson EA,Thomas DP:An International Standard for Low Molecular Weight Heparin. Thromb Hemostas 1988;60:1-7.
6. Holmer E: Anticoagulant properties of heparin and heparin fractions. Scand J Haematol 1980;24 (Suppl 35):25-34.
7. Griffith MJ: Covalent modification of human alpha-thrombin with pyridoxat 5-phosphate. J Biol Chem 1979;254:3401-3406.
8. Gitel SN: Evidence of a catalytic role of heparin in coagulation reactions. In: Bradshaw RA and Wessler ST (hrgs). Heparin, Structure, Function and Clinical Implications. Plenum Press, New York, London, 1975; 243.
9. Harenberg J, Stehle G, Augustin J, Zimmermann R:Comparative Human Pharmacology of Low Molecular Weight Heparins. Sem Thromb Hemost 1989;15:414-423.
10. Barrowcliffe TW, Johnson EA, Eggleton CA,Thomas CA: Anticoagulant services of lung and mucous heparins. Thromb. Res. 1977;12:27-36.
11. Harenberg J: Pharmacology of Low Molecular Weight Heparins. Sem Thromb Hemostas 1990;16 (Suppl):12-18.
12. Merton RE, Thomas DP: Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thrombus Haemostas 1987;58:839-846
13. Teien AN, Bjornson J: Heparin elimination in uraemic patients on haemo-dialysis Stand J Haemat 1976;17:19-25.
14. Andrassy K, Salzmann W, Saggau W, Storch H, Ritz E: Is more heparin necessary for low-dose heparin prophylaxis in uremic patients? Thrombos Haemostas 1981;46:740-742.
15. Teien AN: Heparin elimination in patients with liver cirrhosis Thromb Haemostas 1977;38:701-705.
16. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade J.F, Yung WL:Heparin Kinetics in Venous Thrombosis and Pulmonary Embolism. Circulation 1976; 53:691-695.
17. Harenberg J, Schneider D, Heilmann L, Wolf H: Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993;23:314-320.
18. Wegmann R, Garraud R: Le problème de l'absorption cutanée de l'héparine. Presse Méd 1961;69:898-902.
19. Ekre H-PT, Fjellner B, Hagermark O: Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmac 1986;8:277-286
20. Ekre H-PT: Inhibition of human an guinea pig complement by heparin fractions differing in affinity for antithrombin III or in average molecular weight, Int J Immunopharmac 1985;7:277-280
21. Stuttgen G, Panse P, Bauer E: Heparin and mucopolysaccharide polysulfuric acid ester permeate human skin. Z Hautkr 1989;64:756,761-762, 765
22. Bergqvist D, Brunkwall J, Jensen N, Persson NH: Treatment of superficial thrombophlebitis. A comparative trial between placebo, Hirudoid cream and piroxicam gel. Ann Chir Gynaecol 1990;79:92-96.
23. Harenberg J, Bohme J, Stehle G, Heene DL-Resorption subkutaner Hämatome. Klinikarzt 1993,6.35-39.
24. PIOPED Investigators-Value of the Ventilation/Perfusion Scan in Acute Pulmonary Embolism. JAMA 1990;263.2753-2759.
25. Zilliacus H: On the specific treatment of thrombosis and pulmonary embolism with anticoagulants with particular reference to the post-thrombotic sequelae. Acta Med Scand 1946;171:1.
26. Murray DWG, Jacques L, Perret TS, Best CH: Heparin and the thrombosis of veins following Injury. Surgery 1937;2:163-187.
27. Crafoord C: Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937;79:407-425
28. Bauer G: Heparin therapy in acute deep venous thrombosis. JAMA 1946;131:196.
29. Murray G: Anticoagulant therapy with heparin. Am J Med 1947;3:468-471.
30. Barritt DW, Lond MD, Jordon SC, Briest MB: Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial. Lancet 1960;1: 1309-1312.
31. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW: Subcutaneous Heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116:279-284.
32. Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle EC, Mall K Blauth M, Usadel KH, Heene OL: Therapeutic application of subcutaneous low molecular weight heparin in acute venous thrombosis. Haemostasis 1990;20 (Suppl.1):205-219.
33. Leizorovicz A, Simonneau G, Decousus H, Boissel JP: Comparison of efficacy and safety of low molecular weight heparins and unfractiontated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-304.
34. Lensing AW, Prins MH, Davidson BL, Hirsh J: Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Int Med 1995;155:601-607.
35. Harenberg J, Schmitz-Huebner U (1997) Therapie der Beinvenenthrombose mit niedermolekularen Heparinen. Dtsch Ärztebl 94:A-2257-2260
36. Bachmann F: Die Behandlung der tiefen Venenthrombose mit nieder-molekularem heparin. Schweiz Med Wochenschr 1994;124:169-178.
37. Levine M, Gent M, Hirsh J, Leclerc J, Andersen D, Weitz J, Ginsberg JS, Turpie AG, Demers C, Kovacs M, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein-thrombosis. N Engl J Med 1996;334:677-681.
38. Koopman MMW, Prandoni P, Piovella F, Ockford PA, Brandjes DP, Van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH et al: Treatment of patients with proximal-vein thrombosis with Intravenous infrationated heparin in hospital compared with subcutaneous low-molecular-weight heparin out of hospital or with early discharge. N Engl J Med 1996;334:682-687.
39. Columbus investigators (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337:657-662
40. Harenberg J, Roebruck P, Heene DL on behalf of the HESIM-group: Subcutaneous low-molecular-weight heparin versus standard heparin in the prevention of thromboembolism in medical inpatients. Haemostasis 1996;26:127-139.
41. Lechler E, Schramm W, Flosbach CW, and THE PRIME-Study group: A randomized, multicentre dobule blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Ann Hematol 1994;68 (Suppl. II):52 Abstr.
42. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C: Heparin-associated thrombocytopenia isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.Thromb Haemostas 1994;71:247-251.
43. Greinacher A, Mueller-Eckhardt C: Diagnostik der Heparin-assoziierten Thrombozytopenie. Deutsch Med Wochenschr 1991;16:1479-1482.
44. Harenberg J, Huhle G, Piazolo L, Wang L, Heene DL (1997) Anticoagulation in patients with heprain-induced thrombocytopenia type II. Semin Thromb Hemost 23:189-196